Indivior Pharmaceuticals, Inc.
INDVIndivior is an American pharmaceuticals company. Established as a division of Reckitt Benckiser in 1994 and demerged from that company in December 2014, it is focussed on substitution products for opioid addiction. It is listed on the London Stock Exchange and on the NASDAQ Global Select Market.
Drugs in Pipeline
0
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
2 upcoming, 0 past
INDV Earnings Report
EPS Est: $0.97 | FQ end 2026-06
Acquisition — Supernus Pharmaceuticals
Supernus Pharmaceuticals and Indivior Pharmaceuticals announced an all-stock merger agreement. Deal terms and closing date not specified in the article.
No drugs found in this phase.
Full breakdown — the signals behind the verdict
Frequently asked questions
When is Indivior Pharmaceuticals, Inc.'s next FDA catalyst?→
Indivior Pharmaceuticals, Inc.'s (INDV) next tracked catalyst is a Earnings expected August 4, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track INDV biotech catalysts?→
Add INDV to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Indivior Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.